Safety and activity of anti-PD-L1 antibody in patients with advanced cancer

Cited by (1,051)

Items 101–200 of 1,051

1. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
   Taku Okazaki, Shunsuke Chikuma, Yoshiko Iwai, Sidonia Fagarasan, Tasuku Honjo · 2013 · Nature Immunology
2. Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study
   Lesokhin, Alexander M., Ansell, Stephen M., Armand, Philippe, Scott, Emma C., Halwani, Ahmad, Gutierrez, Martin, Millenson, Michael M., Cohen, Adam D., Schuster, Stephen J., Lebovic, Daniel et al. · 2016 · Journal of Clinical Oncology
3. Coinhibitory Pathways in Immunotherapy for Cancer
   Susanne H.C. Baumeister, Gordon James Freeman, Glenn Dranoff, Arlene H. Sharpe · 2016 · Annual Review of Immunology
4. Phagocytosis checkpoints as new targets for cancer immunotherapy
   Mingye Feng, Wen Jiang, Betty Y.S. Kim, Cheng Cheng Zhang, Yang‐Xin Fu, Irving L. Weissman · 2019 · Nature reviews. Cancer
5. β-Catenin Activation Promotes Immune Escape and Resistance to Anti–PD-1 Therapy in Hepatocellular Carcinoma
   Ruiz de Galarreta, Marina, Bresnahan, Erin, Molina-Sánchez, Pedro, Lindblad, Katherine E., Maier, Barbara, Sia, Daniela, Puigvehi, Marc, Miguela, Verónica, Casanova-Acebes, María, Dhainaut, Maxime et al. · 2019 · Cancer Discovery
6. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease
   Liu, Jing, Blake, Stephen J., Yong, Michelle C.R., Harjunpää, Heidi, Ngiow, Shin Foong, Takeda, Kazuyoshi, Young, Arabella, O'Donnell, Jake S., Allen, Stacey, Smyth, Mark J. et al. · 2016 · Cancer Discovery
7. Pseudoprogression and Immune-Related Response in Solid Tumors
   Victoria L. Chiou, Mauricio Burotto · 2015 · Journal of Clinical Oncology
8. Management of toxicities of immune checkpoint inhibitors
   Spain, Lavinia, Diem, Stefan, Larkin, James · 2016 · Cancer Treatment Reviews
9. The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures
   Jérôme Galon, Helen K. Angell, Davide Bedognetti, Francesco Maria Marincola · 2013 · Immunity
10. Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway
    Kim C. Ohaegbulam, Amer Assal, Eszter Lázár‐Molnár, Yu Yao, Xingxing Zang · 2014 · Trends in Molecular Medicine
11. Oral squamous cell carcinomas: state of the field and emerging directions
    Yunhan Tan, Zhihan Wang, Mengtong Xu, Bowen Li, Zhao Huang, Siyuan Qin, Edouard Collins Nice, Jing Tang, Canhua Huang · 2023 · International Journal of Oral Science
12. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
    Hsu, Joy, Hodgins, Jonathan J., Marathe, Malvika, Nicolai, Chris J., Bourgeois-Daigneault, Marie-Claude, Trevino, Troy N., Azimi, Camillia S., Scheer, Amit K., Randolph, Haley E., Thompson, Thornton W. et al. · 2018 · Journal of Clinical Investigation
13. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
    Benjamin J. Chen, Bjoern Chapuy, Jing Ouyang, Heather H. Sun, Margaretha G.M. Roemer, Mina L. Xu, Hongbo Yu, Christopher D.�M. Fletcher, Gordon James Freeman, Margaret Ann Shipp et al. · 2013 · Clinical Cancer Research
14. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
    Joseph Francis McLaughlin, Gang Han, Kurt Alex Schalper, Daniel Carvajal‐Hausdorf, Vasiliki Pelekanou, Jamaal Rehman, Vamsidhar Velcheti, Roy S. Herbst, Patricia Mucci LoRusso, David L. Rimm · 2015 · JAMA Oncology
15. Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
    Rafiq, Sarwish, Yeku, Oladapo O, Jackson, Hollie J, Purdon, Terence J, van Leeuwen, Dayenne G, Drakes, Dylan J, Song, Mei, Miele, Matthew M, Li, Zhuoning, Wang, Pei et al. · 2018 · Nature Biotechnology
16. An intra-tumoral niche maintains and differentiates stem-like CD8 T cells
    Caroline S. Jansen, Nataliya Prokhnevska, V. Master, M. Sanda, J. Carlisle, M. Bilen, M. Cardenas, S. Wilkinson, R. Lake, A. Sowalsky et al. · 2019 · Nature
17. The immunosuppressive tumour network: myeloid‐derived suppressor cells, regulatory T cells and natural killer T cells
    Dennis Lindau, Paul R. Gielen, Michiel Kroesen, Pieter Wesseling, Gosse J. Adema · 2012 · Immunology
18. Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
    van Rooij, Nienke, van Buuren, Marit M., Philips, Daisy, Velds, Arno, Toebes, Mireille, Heemskerk, Bianca, van Dijk, Laura J.A., Behjati, Sam, Hilkmann, Henk, el Atmioui, Dris et al. · 2013 · Journal of Clinical Oncology
19. Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
    Amita Patnaik, Soonmo Peter Kang, Drew Warren Rasco, Kyriakos P. Papadopoulos, Jeroen Elassaiss‐Schaap, Muralidhar Beeram, Ronald L. Drengler, Cong Chen, Lon S. Smith, Guillermo Espino et al. · 2015 · Clinical Cancer Research
20. A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response
    Paul F. Robbins, Sadik H. Kassim, Thai L.N. Tran, Jessica S. Crystal, Richard A. Morgan, Steven A. Feldman, James Chih‐Hsin Yang, Mark E. Dudley, John R. Wunderlich, Richard Mark Sherry et al. · 2014 · Clinical Cancer Research
21. Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial
    O’Reilly, Eileen M., Oh, Do-Youn, Dhani, Neesha, Renouf, Daniel J., Lee, Myung Ah, Sun, Weijing, Fisher, George, Hezel, Aram, Chang, Shao-Chun, Vlahovic, Gordana et al. · 2019 · JAMA Oncology
22. Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer.
    Lastwika, Kristin J., Wilson, Willie, Li, Qing Kay, Norris, Jeffrey, Xu, Haiying, Ghazarian, Sharon R., Kitagawa, Hiroshi, Kawabata, Shigeru, Taube, Janis M., Yao, Sheng et al. · 2016 · Cancer Research
23. The Next Decade of Immune Checkpoint Therapy
    Sharma, Padmanee, Siddiqui, Bilal A., Anandhan, Swetha, Yadav, Shalini S., Subudhi, Sumit K., Gao, Jianjun, Goswami, Sangeeta, Allison, James P. · 2021 · Cancer Discovery
24. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group
    Hideho Okada, Michael Weller, Raymond Y. Huang, Gaetano Finocchiaro, Mark R. Gilbert, Wolfgang Wick, Benjamin M. Ellingson, Naoya Hashimoto, Ian F. Pollack, Alba Ariela Brandes et al. · 2015 · The Lancet Oncology
25. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
    Chen, J., Jiang, C.C., Jin, L., Zhang, X.D. · 2016 · Annals of Oncology
26. Disruption of CXCR2-Mediated MDSC Tumor Trafficking Enhances Anti-PD1 Efficacy
    Highfill, Steven L., Cui, Yongzhi, Giles, Amber J., Smith, Jillian P., Zhang, Hua, Morse, Elizabeth, Kaplan, Rosandra N., Mackall, Crystal L. · 2014 · Science Translational Medicine
27. Therapeutic vaccines for cancer: an overview of clinical trials
    Ignacio Melero, Gustav Gaudernack, Winald R. Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas J. Thatcher, John Wagstaff, Christoph Carl Zielinski, Ian Faulkner et al. · 2014 · Nature Reviews Clinical Oncology
28. Evidence for a Role of the PD-1:PD-L1 Pathway in Immune Resistance of HPV-Associated Head and Neck Squamous Cell Carcinoma
    Sofía Lyford-Pike, Shiwen Peng, Geoffrey D. Young, Janis Marie Taube, William H. Westra, Belinda Akpeng, Tullia Carmela Bruno, Jeremy D. Richmon, Hao Wang, Justin A. Bishop et al. · 2013 · Cancer Research
29. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy
    Lais Osmani, Frederic Barton Askin, Edward Gabrielson, Qing Kay Li · 2017 · Seminars in Cancer Biology
30. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells
    Rupp, Levi J., Schumann, Kathrin, Roybal, Kole T., Gate, Rachel E., Ye, Chun J., Lim, Wendell A., Marson, Alexander · 2017 · Scientific Reports
31. Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis
    Schietinger, Andrea, Philip, Mary, Krisnawan, Varintra E., Chiu, Edison Y., Delrow, Jeffrey J., Basom, Ryan S., Lauer, Peter, Brockstedt, Dirk G., Knoblaugh, Sue E., Hämmerling, Günter J. et al. · 2016 · Immunity
32. Programmed death ligand-1 expression in non-small cell lung cancer
    Vamsidhar Velcheti, Kurt Alex Schalper, Daniel E Carvajal, Valsamo Anagnostou, Konstantinos Nikolaos Syrigos, Mario Sznol, Roy S. Herbst, Scott N. Gettinger, Lieping Chen, David L. Rimm · 2013 · Laboratory Investigation
33. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
    Crespo, Joel, Sun, Haoyu, Welling, Theodore H, Tian, Zhigang, Zou, Weiping · 2013 · Current Opinion in Immunology
34. m6A mRNA demethylase FTO regulates melanoma tumorigenicity and response to anti-PD-1 blockade
    Seungwon Yang, Jiangbo Wei, Yan‐Hong Cui, Gayoung Park, Palak Shah, Yu Lin Deng, Andrew E. Aplin, Zhike Lu, Seungmin Hwang, Chuan He et al. · 2019 · Nature Communications
35. Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors
    Jaikumar Duraiswamy, Karen M. Kaluza, Gordon James Freeman, George Coukos · 2013 · Cancer Research
36. High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
    Krieg, Carsten, Nowicka, Malgorzata, Guglietta, Silvia, Schindler, Sabrina, Hartmann, Felix J, Weber, Lukas M, Dummer, Reinhard, Robinson, Mark D, Levesque, Mitchell P, Becher, Burkhard · 2018 · Nature Medicine
37. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
    Akintunde Akinleye, Zoaib Rasool · 2019 · Journal of Hematology & Oncology
38. Guidelines of care for the management of primary cutaneous melanoma
    Susan M. Swetter, Hensin Tsao, Christopher Keram Bichakjian, Clara N. Curiel‐Lewandrowski, David E. Elder, Jeffrey E. Gershenwald, Valerie Guild, Jane Margaret Grant-Kels, Allan C. Halpern, Timothy M. Johnson et al. · 2018 · Journal of the American Academy of Dermatology
39. Building better monoclonal antibody-based therapeutics
    George J. Weiner · 2015 · Nature reviews. Cancer
40. Management of non-small-cell lung cancer: recent developments
    Martin Reck, David Felix Heigener, Tony S.K. Mok, Jean‐Charles Soria, Klaus Friedrich Rabe · 2013 · The Lancet
41. Vaccines for established cancer: overcoming the challenges posed by immune evasion
    Sjoerd H. van der Burg, Ramon Arens, FERRY A. OSSENDORP, Thorbald van Hall, Cornelis J.M. Melief · 2016 · Nature reviews. Cancer
42. Regulatory T cells in cancer immunotherapy
    Hiroyoshi Nishikawa, Shimon Sakaguchi · 2014 · Current Opinion in Immunology
43. Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
    Kristin G. Anderson, Ingunn M. Stromnes, Philip D. Greenberg · 2017 · Cancer Cell
44. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy
    Yuanzeng Min, Kyle C. Roche, Shaomin Tian, Michael Joseph Eblan, Karen P. McKinnon, Joseph Michael Caster, Shengjie Chai, Laura E. Herring, Longzhen Zhang, Tian Zhang et al. · 2017 · Nature Nanotechnology
45. Neoantigen vaccine: an emerging tumor immunotherapy
    Peng Miao, Yongzhen Mo, Yian Wang, Pan Wu, Yijie Zhang, Fang Xiong, Can Jie Guo, Steven Wu, Yong Li, Xiaoling Li et al. · 2019 · Molecular Cancer
46. PDL1 Regulation by p53 via miR-34
    Cortez, Maria Angelica, Ivan, Cristina, Valdecanas, David, Wang, Xiaohong, Peltier, Heidi J., Ye, Yuping, Araujo, Luiz, Carbone, David P., Shilo, Konstantin, Giri, Dipak K et al. · 2016 · JNCI: Journal of the National Cancer Institute
47. Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
    Liza B. John, Christel Devaud, Connie P.M. Duong, Carmen S. M. Yong, Paul A. Beavis, Nicole M. Haynes, Melvyn T. Chow, Mark John Smyth, Michael H. Kershaw, Phillip Kevin Darcy · 2013 · Clinical Cancer Research
48. Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
    Mezzadra, Riccardo, Sun, Chong, Jae, Lucas T., Gomez-Eerland, Raquel, de Vries, Evert, Wu, Wei, Logtenberg, Meike E. W., Slagter, Maarten, Rozeman, Elisa A., Hofland, Ingrid et al. · 2017 · Nature
49. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients
    Patrick Alexander Ott, Frank Stephen Hodi, Caroline Robert · 2013 · Clinical Cancer Research
50. Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
    Byun, David J., Wolchok, Jedd D., Rosenberg, Lynne M., Girotra, Monica · 2017 · Nature Reviews Endocrinology
51. Tumor Immunotherapy Directed at PD-1
    Antoni Ribas · 2012 · New England Journal of Medicine
52. A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer
    Rimm, David L., Han, Gang, Taube, Janis M., Yi, Eunhee S., Bridge, Julia A., Flieder, Douglas B., Homer, Robert, West, William W., Wu, Hong, Roden, Anja C. et al. · 2017 · JAMA Oncology
53. Tolerance and exhaustion: defining mechanisms of T cell dysfunction
    Andrea Schietinger, Philip D. Greenberg · 2013 · Trends in Immunology
54. Challenges and Opportunities for Pancreatic Cancer Immunotherapy
    Bear, Adham S., Vonderheide, Robert H., O'Hara, Mark H. · 2020 · Cancer Cell
55. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
    Kim, KiBem, Skora, Andrew D., Li, Zhaobo, Liu, Qiang, Tam, Ada J., Blosser, Richard L., Diaz, Luis A., Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert et al. · 2014 · Proceedings of the National Academy of Sciences
56. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
    Hudson, William H., Gensheimer, Julia, Hashimoto, Masao, Wieland, Andreas, Valanparambil, Rajesh M., Li, Peng, Lin, Jian-Xin, Konieczny, Bogumila T., Im, Se Jin, Freeman, Gordon J. et al. · 2019 · Immunity
57. Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
    Philippe A. Armand, Margaret Ann Shipp, Vincent Ribrag, Jean‐Marie Michot, Pier Luigi Zinzani, John G. Kuruvilla, Ellen Snyder, Alejandro Daniel Ricart, Arun Balakumaran, Shelonitda Rose et al. · 2016 · Journal of Clinical Oncology
58. Immune Landscape of Viral- and Carcinogen-Driven Head and Neck Cancer
    Anthony Richard Cillo, Cornelius H. L. Kürten, Tracy Tabib, Zengbiao Qi, Sayali Onkar, Ting Wang, Angen Liu, Umamaheswar Duvvuri, Seungwon Kim, Ryan J. Soose et al. · 2020 · Immunity
59. Immunotherapy in Non–Small Cell Lung Cancer: Facts and Hopes
    Deborah B. Doroshow, Miguel F. Sanmamed, Katherine Hastings, Katerina A. Politi, David L. Rimm, Lieping Chen, Ignacio Melero, Kurt Alex Schalper, Roy S. Herbst · 2019 · Clinical Cancer Research
60. Nanoscale Metal–Organic Framework Overcomes Hypoxia for Photodynamic Therapy Primed Cancer Immunotherapy
    Guangxu Lan, Kaiyuan Ni, Ziwan Xu, Samuel S. Veroneau, Yang Song, Wenbin Lin · 2018 · Journal of the American Chemical Society
61. CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions
    Masao Hashimoto, Alice Oliffson Kamphorst, Se Jin Im, Haydn Thomas Kissick, Rathi Narayana Pillai, Suresh S. Ramalingam, Koichi Araki, Rafi Ahmed · 2018 · Annual Review of Medicine
62. Renal cell carcinoma
    Eric Jonasch, Jianjun Gao, W. Kimryn Rathmell · 2014 · BMJ
63. Stereotactic Radiation Therapy Augments Antigen-Specific PD-1–Mediated Antitumor Immune Responses via Cross-Presentation of Tumor Antigen
    Andrew B. Sharabi, Christopher J. Nirschl, Christina M. Kochel, Thomas R. Nirschl, Brian J. Francica, Esteban Velarde, Theodore L. DeWeese, Charles G. Drake · 2014 · Cancer Immunology Research
64. Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1
    Daniel S. Chen, Bryan A. Irving, Frank Stephen Hodi · 2012 · Clinical Cancer Research
65. Aberrant PD-L1 expression through 3′-UTR disruption in multiple cancers
    Keisuke Kataoka, Yuichi Shiraishi, Yohei Takeda, Seiji Sakata, Misako Matsumoto, Seiji Nagano, Takuya Maeda, Yasunobu Nagata, Akira Kitanaka, Seiya Mizuno et al. · 2016 · Nature
66. Stem cell fate in cancer growth, progression and therapy resistance
    Nikki K. Lytle, Alison G. Barber, Tannishtha Reya · 2018 · Nature reviews. Cancer
67. DNA Damage and Repair Biomarkers of Immunotherapy Response
    Kent William Mouw, Michael S. Goldberg, Panagiotis A. Konstantinopoulos, Alan D. D’Andrea · 2017 · Cancer Discovery
68. Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
    Kim, J.M., Chen, D.S. · 2016 · Annals of Oncology
69. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer
    Koichi Azuma, Keiichi Ota, Akihiko Kawahara, Satoshi Hattori, Eiji Iwama, Takeshi Harada, Koichiro Matsumoto, Koichi Takayama, Shinzo Takamori, M. Kage et al. · 2014 · Annals of Oncology
70. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies
    Gurbatri, Candice R., Lia, Ioana, Vincent, Rosa, Coker, Courtney, Castro, Samuel, Treuting, Piper M., Hinchliffe, Taylor E., Arpaia, Nicholas, Danino, Tal · 2020 · Science Translational Medicine
71. Cancer immunotherapies targeting the PD-1 signaling pathway
    Yoshiko Iwai, Junzo Hamanishi, Kenji Chamoto, Tasuku Honjo · 2017 · Journal of Biomedical Science
72. Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
    Jennifer Landsberg, Judith D. Sirokay, Marcel Renn, Tobias Bald, Meri Rogava, Mira Cron, Martina Fatho, Volker Lennerz, Thomas Wölfel, Michael Hölzel et al. · 2012 · Nature
73. Clinical blockade of PD1 and LAG3 — potential mechanisms of action
    Linh T. Nguyen, Pamela S. Ohashi · 2014 · Nature reviews. Immunology
74. Dermatologic Reactions to Immune Checkpoint Inhibitors
    Vincent Sibaud · 2017 · American Journal of Clinical Dermatology
75. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
    Kyle C. Strickland, Brooke E. Howitt, Sachet Ashok Shukla, Scott J. Rodig, Lauren L. Ritterhouse, Joyce F. Liu, Judy Ellen Garber, Dipanjan Chowdhury, Catherine J. Wu, Alan D. D’Andrea et al. · 2016 · Oncotarget
76. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade
    Fu, Juan, Kanne, David B., Leong, Meredith, Glickman, Laura Hix, McWhirter, Sarah M., Lemmens, Edward, Mechette, Ken, Leong, Justin J., Lauer, Peter, Liu, Weiqun et al. · 2015 · Science Translational Medicine
77. Drug resistance and new therapies in colorectal cancer
    Jeught, Kevin Van der, Xu, Han-Chen, Li, Yu-Jing, Lu, Xiong-Bin, Ji, Guang · 2018 · World Journal of Gastroenterology
78. Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study
    H. R. Ali, Leon Chlon, P. Pharoah, F. Markowetz, C. Caldas · 2016 · PLoS Medicine
79. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer
    Yearley, Jennifer H., Gibson, Christopher, Yu, Ni, Moon, Christina, Murphy, Erin, Juco, Jonathan, Lunceford, Jared, Cheng, Jonathan, Chow, Laura Q.M., Seiwert, Tanguy Y. et al. · 2017 · Clinical Cancer Research
80. Melanoma
    Dirk Schadendorf, David E. Fisher, Claus Garbe, Jeffrey E. Gershenwald, Jean‐Jacques Grob, Allan C. Halpern, Meenhard Herlyn, Michael Armando Marchetti, Grant A. McArthur, Antoni Ribas et al. · 2015 · Nature Reviews Disease Primers
81. Guidelines of care for the management of primary cutaneous melanoma
    Christopher Keram Bichakjian, Allan C. Halpern, Timothy M. Johnson, Antoinette F. Hood, James M. Grichnik, Susan M. Swetter, Hensin Tsao, Victoria Barbosa, Tsu‐Yi Chuang, Madeleine A. Duvic et al. · 2011 · Journal of the American Academy of Dermatology
82. Pancreatic Ductal Adenocarcinoma: Current and Evolving Therapies
    Aleksandra Adamska, Alice Domenichini, Marco Falasca · 2017 · International Journal of Molecular Sciences
83. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy
    Tianyu Tang, Xing Huang, Gang Zhang, Zhengtao Hong, Xueli Bai, Tingbo Liang · 2021 · Signal Transduction and Targeted Therapy
84. The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
    Bardhan, Kankana, Anagnostou, Theodora, Boussiotis, Vassiliki A. · 2016 · Frontiers in Immunology
85. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
    Picarda, Elodie, Ohaegbulam, Kim C., Zang, Xingxing · 2016 · Clinical Cancer Research
86. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline – Update 2016
    Claus Garbe, Ketty Peris, Axel Hauschild, Philippe Saïag, Mark Ross Middleton, Lars Bastholt, Jean‐Jacques Grob, Josep Malvehy, Julia Newton‐Bishop, Alexander Stratigos et al. · 2016 · European Journal of Cancer
87. Deciphering and Reversing Tumor Immune Suppression
    Gregory T. Motz, George Coukos · 2013 · Immunity
88. Engineering synthetic vaccines using cues from natural immunity
    Darrell J. Irvine, Melody A. Swartz, Gregory Lee Szeto · 2013 · Nature Materials
89. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
    Scott D. Brown, Robin M. Warren, Ewan A. Gibb, Spencer D. Martin, John Joseph Spinelli, Brad H. Nelson, Robert A. Holt · 2014 · Genome Research
90. Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
    Baran, Burcin, Mert Ozupek, Nazli, Yerli Tetik, Nihal, Acar, Emine, Bekcioglu, Omer, Baskin, Yasemin · 2018 · Gastroenterology Research
91. Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
    Weide, Benjamin, Martens, Alexander, Hassel, Jessica C., Berking, Carola, Postow, Michael A., Bisschop, Kees, Simeone, Ester, Mangana, Johanna, Schilling, Bastian, Di Giacomo, Anna Maria et al. · 2016 · Clinical Cancer Research
92. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
    Heng Lin, Shuang Wei, Elaine M. Hurt, Michael D. Green, Lili Zhao, Linda Vatan, Wojciech Szeliga, Ronald Herbst, Paul W. Harms, Leslie Anne Fecher et al. · 2018 · Journal of Clinical Investigation
93. PD‐L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint blockade
    Peng, Qi, Qiu, Xiangyan, Zhang, Zihan, Zhang, Silin, Zhang, Yuanyuan, Liang, Yong, Guo, Jingya, Peng, Hua, Chen, Mingyi, Fu, Yang-Xin et al. · 2020 · Nature Communications
94. Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers
    Wouter Scheper, Sander Kelderman, Lorenzo F. Fanchi, Carsten Linnemann, Gavin M. Bendle, Marije A. J. de Rooij, Christian Hirt, Riccardo Mezzadra, Maarten Slagter, Krijn Kristian Dijkstra et al. · 2018 · Nature Medicine
95. In vivo molecular imaging for immunotherapy using ultra-bright near-infrared-IIb rare-earth nanoparticles
    Zhong, Yeteng, Ma, Zhuoran, Wang, Feifei, Wang, Xi, Yang, Yijun, Liu, Yulai, Zhao, Xiang, Li, Jiachen, Du, Haotian, Zhang, Mingxi et al. · 2019 · Nature Biotechnology
96. Cancer-associated fibroblasts induce antigen-specific deletion of CD8 + T Cells to protect tumour cells
    Lakins, Matthew A., Ghorani, Ehsan, Munir, Hafsa, Martins, Carla P., Shields, Jacqueline D. · 2018 · Nature Communications
97. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    Kathleen Margaret Mahoney, Gordon James Freeman, David F. McDermott · 2015 · Clinical Therapeutics
98. Immune checkpoint blockade in infectious diseases
    Michelle Wykes, Sharon R. Lewin · 2017 · Nature reviews. Immunology
99. Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours
    Han Yao, Jiang Lan, Chushu Li, Hubing Shi, Jean‐Philippe Brosseau, Huanbin Wang, Haojie Lu, Caiyun Fang, Yao Zhang, Lunxi Liang et al. · 2019 · Nature Biomedical Engineering
100. The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
     Tang Qing, Yun Chen, Xiaojuan Li, Shunqin Long, Yao Shi, Yaya Yu, Wanyin Wu, Ling Han, Sumei Wang · 2022 · Frontiers in Immunology